FOLFIRI与FOLFOX4方案一线治疗晚期大肠癌的疗效观察  

The Response of FOLFIRI Versus FOLFOX4 Regimens in the First-line Treatment for Advanced Colorectal Cancer

作　　者：梁永君[1] 井小会[1] 刘玉刚[1] 郭运杰[1] 王粉[1] 

机构地区：[1]平顶山市第一人民医院,河南平顶山467000

出　　处：《中国肿瘤》2013年第3期232-234,共3页China Cancer

摘　　要：[目的]比较FOLFIRI方案与FOLFOX4方案一线治疗晚期大肠癌的疗效和不良反应。[方法]将56例晚期大肠癌患者随机分为两组:FOLFIRI方案组(n=28)和FOLFOX4方案组(n=28),2个周期后观察疗效和不良反应。[结果]FOLFIRI组有效率(RR)为35.7%,中位肿瘤进展时间(TTP)为7.5个月,中位总生存期(mOS)为15个月,1、2、3年生存率分别为89.29%、73.08%和40.00%;FOLFOX4组RR为39.3%,TTP为7.5个月,mOS为16个月,1、2、3年生存率分别为89.29%、72.00%和45.45%;两组比较各项指标差异无统计学意义(P>0.05)。不良反应中FOLFIRI组腹泻发生率高于FOLFOX4组,神经毒性发生率明显低于FOLFOX4组。[结论]FOLFIRI方案与FOLFOX4方案的疗效相当,都可作为晚期大肠癌的一线标准方案。[Purpose ] To compare the efficacy and toxicity of FOLFIRI and FOLFOX4 regimens in the first- line treatment fbr advanced colorectal cancer. [Methods] Fifty-six patients with advanced colorectal cancer were randomly divided into two groups： FOLFIRI group（n=28） and FOLFOX4 group（n=28）.The response and toxicity were evaluated after 2 cycles of chemotherapy. [Results] In FOLFIRI group the response rate（RR）, median time to tumor progression （Tl＇P）,median overall survival （mOS） and 1-,2-,3- survival rates were 35.7% ,7.5 months, 15 months,89.29% ,73.08% and 40.00% ,respectively; while in FOLFOX4 group those were 39.3%, 7.5 months, 16 months, 89.29%,72.00% and 45.45% respectively.There was no significant difference between the 2 groups （P〉0.05）. The incidence rate of diarrhea in FOLFIRI group was higher than that in FOLFOX4 group; while the incidence of neurotoxicity was significantly lower than that in FOLFOX4 group. [Conclusion ] FOLFIRI and FOLFOX4 regimens have similar treatment response,which can be used as a fi^t-line regimen for advanced colorectal cancer.

关 键 词：奥沙利铂 氟尿嘧啶 亚叶酸钙 一线治疗 大肠癌 

分 类 号：R735.34[医药卫生—肿瘤]